Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | EVP, Corp Strategy & Develop | August 10, 2026 | August 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date August 10, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,041 |
Reported balance
After 2026-08-10 transaction · row 1
1 source rowRow 1 · 2026-08-10 · Gift · Disposed 257 · Balance 31,041 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2019 Filed Feb 26, 2019 19:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 322 | $144.67 | $46,583.74 |
DisclosureSEC source: 0001127602-19-008324 · form4.xml · nonDerivative · entry 3 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,243 Read SEC document |
| February 23, 2019 Filed Feb 26, 2019 19:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 316 | $144.67 | $45,715.72 |
DisclosureSEC source: 0001127602-19-008324 · form4.xml · nonDerivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,565 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 19:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 12,170 | $0.00 Strike: $144.67 | $0.00 |
DisclosureSEC source: 0001127602-19-008324 · form4.xml · derivative · entry 4 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,170 Underlying: Common Stock · 12,170 shares Expires 2024-02-22 F2 · derivative.exercise_date: Stock options vest as follows: 3,042 options vest one (1) year from the date of grant, 3,043 options vest two (2) years from the date of grant, 3,042 options vest three (3) years from the date of grant, and 3,043 options vest four (4) years from the date of grant. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 19:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 2,854 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-008324 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,881 F1 · security: Consists of 2,854 unvested restricted stock units that vest as follows: 713 shares vest one (1) year from the date of issuance, 714 shares vest two (2) years from the date of issuance, 713 shares vest three (3) years from the date of issuance, and 714 shares vest four (4) years from the date of issuance. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.